Visit Komen.org
Lower Your Risk
Prev Thread Prev Thread   Next Thread Next Thread
 Zoladex Shows Fertility Advantages in Treatment of Early Breast Cancer
Author Message
Komen Admin

  • Total Posts : 892
  • Reward points : 13455
  • Joined: 2/3/2006
  • Location: Dallas, TX
  • Status: offline
Zoladex Shows Fertility Advantages in Treatment of Early Breast Cancer - Friday, June 13, 2014 1:50 PM
At the 2014 American Society of Clinical Oncology® meeting in Chicago, researchers reported that women with early stage hormone receptor-negative (HR-negative) breast cancer who were treated with Zoladex® (goserelin) had a reduced rate of ovarian failure at 2 years. In addition, the Zoladex group had higher rates of patients becoming pregnant, patients giving birth, and patients with one or more deliveries (or still pregnant).  
HR-negative breast cancer is a type of breast cancer that does not respond to hormonal therapy, treatment that lowers the amount of estrogen in the body or blocks its action. A problem associated with the chemotherapy used to treat HR-negative breast cancer is ovarian failure (loss of function before the age of 40). 
In this study conducted with multiple research groups, premenopausal women with early stage HR-negative breast cancer were enrolled and treated with a regimen of cyclophosphamide-containing chemotherapy. Patients were then randomized to take either additional Zoladex or just chemotherapy alone. 
Researchers reported that at two years only 8% of the Zoladex patients encountered ovarian failure as compared to 22% in the chemotherapy-alone group. Other fertility measures improved as well, including pregnancies (21% versus 11%), births (15% versus 7%), and patients with one or more deliveries or still pregnant (18% versus 9%).   
Reference: Moore et al. Phase III trial (Prevention of Early Menopause Study [POEMS]-SWOG S0230) of LHRH analog during chemotherapy to reduce ovarian failure in early-stage, hormone receptor-negative breast cancer: An international intergroup trial of SWOG, IBCSG, ECOG, and CALGB. ASCO 2014; Abstract LBA505. 

Jump to:

Icon Legend and Permission
  • New Messages
  • No New Messages
  • Hot Topic w/ New Messages
  • Hot Topic w/o New Messages
  • Locked w/ New Messages
  • Locked w/o New Messages
  • Read Message
  • Post New Thread
  • Reply to message
  • Post New Poll
  • Submit Vote
  • Post reward post
  • Delete my own posts
  • Delete my own threads
  • Rate post

© 2000-2008 ASPPlayground.NET Forum Version 3.1.5